

15 Setembro, 2022 - no auditório do IPEN/CNEN-SP (Bloco A)

Horário	Tema	Palestrante
09:00	Papel do PSMA PET/CT no câncer de próstata	Paulo Rosado-de-Castro
09:20	Diagnostic performance and clinical impact of ⁶⁸ Ga-PSMA-11 PET/CT imaging in early relapsed prostate cancer after radical Therapy: a prospective multicentre study (IAEA-PSMA study)	Enrique Estrada
09:40	Evolving role of PET based total body imaging and global disease assessment, a revolution in medicine	Abass Alavi
10:00	PSMA PET/CT: critério de avaliação e relatórios padronizados	Sérgio Altino de Almeida
10:20	Intervalo	
10:40	Dosimetry in ¹⁷⁷ Lu-PSMA therapy for kidney and salivary protection	Stefano Severi
11:00	Low dosage ¹⁷⁷ Lu-PSMA therapy in patients at high risk for toxicity	Stefano Severi
11:20	Aspectos práticos: Administração, Cuidados pós-terapia e Imagens pós-tratamento	Letícia Rigo
11:40	TheraP	Juliano Cerci
12:00	Almoço	
14:00	VISION	Phillip Kuo
14:20	PSMA PET/CT baseline imaging as a prognostic tool for clinical outcome ¹⁷⁷ Lu-PSMA	Phillip Kuo
14:40	Reader agreement of PSMA PET/CT interpretation to determine patient eligibility for ¹⁷⁷ Lu-PSMA	Phillip Kuo
15:00	Discussão	Elba Etchebehere
15:20	Intervalo	
15:40	Development of radiotracers	Phillip Kuo
16:00	Development of PSMA theranostics	Phillip Kuo
16:20	Diagnostic PSMA-targeting radiotracers with longer-lived PET isotopes	Vasko Kramer
16:40	Albumin-binding ¹⁷⁷ Lu-PSMA ligands for therapy of mCRPC – what we have learned	Vasko Kramer
17:00	Programa multicêntrico utilizando radioligantes de PSMA para o diagnóstico de terapia de pacientes com câncer de próstata	Emerson Bernades
Encerramento		

Inscrições até dia **9 de Setembro 2022** pelo e-mail:
secretaria.cr@ipen.br